Study of Biostate® in Children With Von Willebrand Disease

Inclusion Criteria: * Male and female subjects between 0 and \<12 years of age * Diagnosed with VWD Type 1, 2A, or 3 * Desmopressin acetate (DDAVP) treatment is ineffective, contraindicated, or not available for subject * von Willebrand factor: ristocetin cofactor (VWF:RCo) is \<20% at screening or the subject has a history of VWF:RCo \<10% * Evidence of vaccination against hepatitis A and B or presence of antibodies against hepatitis A and B due to either a previous infection or prior immunization * Written informed consent given Exclusion Criteria: * Active bleeding immediately prior to initial PK period * Received treatment with DDAVP or a VWF concentrate product for their VWD in the 5 days prior to their first study treatment * Have received aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) within 7 days of commencing the PK period. * Known history or suspicion of having VWF or FVIII inhibitors * Acute or chronic medical condition, other than VWD, which may affect the conduct of the study * Known or suspected hypersensitivity or previous evidence of severe side effects to other FVIII/VWF concentrates * Participation in a clinical study or use of an investigational compound in another study in the 3 months preceding study start * Unwillingness and/or inability to comply with the study requirements